PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TGTX vs. RYTM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between TGTX and RYTM is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

TGTX vs. RYTM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TG Therapeutics, Inc. (TGTX) and Rhythm Pharmaceuticals, Inc. (RYTM). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%80.00%AugustSeptemberOctoberNovemberDecember2025
47.31%
15.50%
TGTX
RYTM

Key characteristics

Sharpe Ratio

TGTX:

1.48

RYTM:

0.80

Sortino Ratio

TGTX:

2.45

RYTM:

1.41

Omega Ratio

TGTX:

1.29

RYTM:

1.17

Calmar Ratio

TGTX:

0.97

RYTM:

1.25

Martin Ratio

TGTX:

8.39

RYTM:

2.43

Ulcer Index

TGTX:

11.59%

RYTM:

16.62%

Daily Std Dev

TGTX:

65.97%

RYTM:

50.85%

Max Drawdown

TGTX:

-100.00%

RYTM:

-92.10%

Current Drawdown

TGTX:

-99.98%

RYTM:

-14.57%

Fundamentals

Market Cap

TGTX:

$4.65B

RYTM:

$3.54B

EPS

TGTX:

-$0.10

RYTM:

-$4.32

Total Revenue (TTM)

TGTX:

$220.82M

RYTM:

$88.30M

Gross Profit (TTM)

TGTX:

$197.58M

RYTM:

$78.35M

EBITDA (TTM)

TGTX:

$17.39M

RYTM:

-$201.06M

Returns By Period

In the year-to-date period, TGTX achieves a -0.80% return, which is significantly lower than RYTM's 2.75% return.


TGTX

YTD

-0.80%

1M

-7.27%

6M

47.31%

1Y

84.09%

5Y*

17.19%

10Y*

7.83%

RYTM

YTD

2.75%

1M

2.49%

6M

15.50%

1Y

37.90%

5Y*

25.74%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

TGTX vs. RYTM — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TGTX
The Risk-Adjusted Performance Rank of TGTX is 8484
Overall Rank
The Sharpe Ratio Rank of TGTX is 8686
Sharpe Ratio Rank
The Sortino Ratio Rank of TGTX is 8686
Sortino Ratio Rank
The Omega Ratio Rank of TGTX is 8282
Omega Ratio Rank
The Calmar Ratio Rank of TGTX is 7878
Calmar Ratio Rank
The Martin Ratio Rank of TGTX is 8989
Martin Ratio Rank

RYTM
The Risk-Adjusted Performance Rank of RYTM is 7171
Overall Rank
The Sharpe Ratio Rank of RYTM is 7272
Sharpe Ratio Rank
The Sortino Ratio Rank of RYTM is 6868
Sortino Ratio Rank
The Omega Ratio Rank of RYTM is 6464
Omega Ratio Rank
The Calmar Ratio Rank of RYTM is 8282
Calmar Ratio Rank
The Martin Ratio Rank of RYTM is 6969
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TGTX vs. RYTM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and Rhythm Pharmaceuticals, Inc. (RYTM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for TGTX, currently valued at 1.48, compared to the broader market-2.000.002.004.001.480.80
The chart of Sortino ratio for TGTX, currently valued at 2.45, compared to the broader market-4.00-2.000.002.004.006.002.451.41
The chart of Omega ratio for TGTX, currently valued at 1.29, compared to the broader market0.501.001.502.001.291.17
The chart of Calmar ratio for TGTX, currently valued at 1.27, compared to the broader market0.002.004.006.001.271.25
The chart of Martin ratio for TGTX, currently valued at 8.39, compared to the broader market0.0010.0020.0030.008.392.43
TGTX
RYTM

The current TGTX Sharpe Ratio is 1.48, which is higher than the RYTM Sharpe Ratio of 0.80. The chart below compares the historical Sharpe Ratios of TGTX and RYTM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00AugustSeptemberOctoberNovemberDecember2025
1.48
0.80
TGTX
RYTM

Dividends

TGTX vs. RYTM - Dividend Comparison

Neither TGTX nor RYTM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

TGTX vs. RYTM - Drawdown Comparison

The maximum TGTX drawdown since its inception was -100.00%, which is greater than RYTM's maximum drawdown of -92.10%. Use the drawdown chart below to compare losses from any high point for TGTX and RYTM. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-45.61%
-14.57%
TGTX
RYTM

Volatility

TGTX vs. RYTM - Volatility Comparison

TG Therapeutics, Inc. (TGTX) has a higher volatility of 17.50% compared to Rhythm Pharmaceuticals, Inc. (RYTM) at 13.26%. This indicates that TGTX's price experiences larger fluctuations and is considered to be riskier than RYTM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
17.50%
13.26%
TGTX
RYTM

Financials

TGTX vs. RYTM - Financials Comparison

This section allows you to compare key financial metrics between TG Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab